MG
UTHR icon

Marex Group’s United Therapeutics UTHR Stock Holding History

Marex Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$732K Buy
+1,351
New +$761K ﹤0.01% 588
2025
Q3 		– Sell
-1,100
Closed -$316K – 1007
2025
Q2 		$316K Sell
1,100
-428
-28% -$128K ﹤0.01% 440
2025
Q1 		$471K Buy
+1,528
New +$524K 0.01% 347

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Marex Group's UTHR Position: Q2 2026 in Review

Marex Group opened a new position in United Therapeutics (UTHR) in Q2 2026: 1,351 shares worth $732K. The stake represents ﹤0.01% of the portfolio and ranks #588 among its holdings. This is a return to the name: Marex Group previously reported a position in UTHR as recently as Q2 2025.

Marex Group first reported a position in UTHR in Q1 2025 and has held it in 3 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Marex Group held 1,351 shares of United Therapeutics worth $732K as of Q2 2026.
  • United Therapeutics was a new Marex Group position in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #588 holding.
  • Marex Group first reported a position in United Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.